Details of the Drug

General Information of Drug (ID: DMV67QO)

Drug Name

Ibalizumab

Synonyms

Hu5A8; TNX-355

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Approved	[1]
Human immunodeficiency virus-1 infection	1C62	Approved	[2]
------------------------------------------------------------------------------------

Drug Type

Antibody

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 3 - 3.5 days [3]
Metabolism: The drug is metabolized via the CD4 receptor internalization [4]
Vd: The volume of distribution (Vd) of drug is 4.8 L []

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD4 (CD4)	TTN2JFW	CD4_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Human immunodeficiency virus infection

ICD Disease Classification

1C62

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
T-cell surface glycoprotein CD4 (CD4)	DTT	CD4	9.36E-04	0.67	2.62

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 761065.
3	Ibalizumab
4	Monotherapy With Anti-CD4 Monoclonal Antibody Cuts Viral Load 10-Fold in 7 Days